Get the Stockscreener App
3.80
16.30%
-0.74
After Hours:
3.80
Outset Medical Inc stock is traded at $3.80, with a volume of 696.61K.
It is down -16.30% in the last 24 hours and down -31.78% over the past month.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
See More
Previous Close:
$4.54
Open:
$4.51
24h Volume:
696.61K
Relative Volume:
0.72
Market Cap:
$68.98M
Revenue:
$114.73M
Net Income/Loss:
$-140.94M
P/E Ratio:
-1.3768
EPS:
-2.76
Net Cash Flow:
$-126.18M
1W Performance:
-13.44%
1M Performance:
-31.78%
6M Performance:
-70.01%
1Y Performance:
-67.52%
1-Day Range:
$3.535
$4.52
1-Week Range:
$3.535
$4.9212
52-Week Range:
$3.10
$21.98
Outset Medical Inc Stock (OM) Company Profile
Name
Outset Medical Inc
Sector
Industry
Phone
669-231-8200
Address
3052 ORCHARD DRIVE, SAN JOSE
Compare OM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OM
Outset Medical Inc
|
3.80 | 82.42M | 114.73M | -140.94M | -126.18M | -2.76 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Outset Medical Inc Stock (OM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-21-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-08-24 | Initiated | BTIG Research | Buy |
| Apr-05-24 | Upgrade | CL King | Neutral → Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-17-23 | Initiated | CL King | Neutral |
| Nov-11-22 | Initiated | RBC Capital Mkts | Outperform |
| Jul-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-18-21 | Initiated | Cowen | Outperform |
| Apr-19-21 | Initiated | Wells Fargo | Overweight |
| Dec-16-20 | Initiated | Oppenheimer | Perform |
| Oct-12-20 | Initiated | Barclays | Overweight |
| Oct-12-20 | Initiated | BofA Securities | Buy |
| Oct-12-20 | Initiated | Goldman | Buy |
| Oct-12-20 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-12-20 | Initiated | SVB Leerink | Mkt Perform |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Outset Medical Inc Stock (OM) Latest News
BTIG Lowers Price Target for Outset Medical (OM) to $15, Maintai - GuruFocus
Outset Medical stock dips on Q4 EPS miss - MassDevice
Outset Medical Inc (OM) Q4 2025 Earnings Call Highlights: Strate - GuruFocus
Outset Medical: Stabilizing Execution, Improving Margins, and Balanced 2026 Outlook Support Buy Rating Despite Lower Target - TipRanks
Earnings call transcript: Outset Medical Q4 2025 reports revenue growth By Investing.com - Investing.com India
Outset Medical (OM) Sets 2026 Revenue and Margin Targets - GuruFocus
Outset Medical Q4 Earnings Call Highlights - Yahoo Finance
Outset Medical earnings missed by $0.60, revenue fell short of estimates - Investing.com Canada
OM: Revenue up 5% to $119.5M, margin expands, and next-gen Tablo FDA-cleared for 2026 growth - TradingView
Earnings call transcript: Outset Medical Q4 2025 reports revenue growth - Investing.com
Outset Medical Inc. (OM) Misses Q4 EPS by 60c - StreetInsider
Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Outset Medical Q4 Earnings Report: What Investors Need to Know - Benzinga
Dialysis device maker Outset cuts 2025 loss to $81.7M, gets FDA clearance - Stock Titan
Fund Flows: Can Outset Medical Inc sustain earnings growth2025 Valuation Update & Verified Technical Trade Signals - baoquankhu1.vn
Outset Medical Q4 2025 earnings preview - MSN
Outset Medical Inc (OM) Q4 2025: Everything You Need To Know Ahe - GuruFocus
Stifel Lowers Price Target on Outset Medical, Inc. (OM) to $8, Maintains Buy Rating - Finviz
Stifel lowers price target on Outset Medical, Inc. (OM) to $8, maintains buy rating - MSN
11 High Growth Micro-cap Stocks to Buy - Insider Monkey
Outset Medical Secures Key FDA Clearance for Next-Generation Dialysis System - AD HOC NEWS
Outset Medical (NASDAQ:OM) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Outset Medical, Inc. (NASDAQ:OM) Held Back By Insufficient Growth Even After Shares Climb 35% - simplywall.st
Is Outset Medical Inc benefiting from innovation trendsJuly 2025 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn
Outset Medical (NASDAQ:OM) Rating Increased to Hold at Wall Street Zen - MarketBeat
What are the future prospects of Outset Medical Inc.Weekly Earnings Recap & Reliable Momentum Entry Alerts - mfd.ru
Outset Medical, Inc. (OM) Investor Outlook: Is A 133.83% Upside On The Horizon? - DirectorsTalk Interviews
OM Stock Gains on FDA Clearance for Next-Gen Tablo Dialysis System - sharewise.com
Quarterly Earnings: What is Outset Medical Incs 5 year growth outlookMarket Activity Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Guidance Update: Is Outset Medical Inc being accumulated by smart moneyJuly 2025 Volume & Long-Term Safe Investment Plans - baoquankhu1.vn
Outset Medical secures FDA clearance for Tablo haemodialysis system - Yahoo Finance
Outset Medical stock jumps after FDA clears next-gen Tablo platform - Investing.com Australia
Is Outset Medical Inc. stock risky to hold nowQuarterly Portfolio Report & Long-Term Growth Stock Strategies - mfd.ru
Outset Medical Gets FDA Clearance for Tablo Hemodialysis System - marketscreener.com
Outset Medical wins FDA nod for next-gen Tablo hemodialysis system - MassDevice
Outset Medical, Inc. Announces 510(K) Clearance by the U.S. Food and Drug Administration of Its Next-Generation Tablo Platform - marketscreener.com
Outset Medical Secures FDA Clearance For Next-Generation Tablo Hemodialysis System - Nasdaq
Outset Medical (OM) Gains FDA Clearance for Advanced Tablo Platf - GuruFocus
Outset Medical’s Tablo dialysis system meets FDA cybersecurity standards - Investing.com
Outset Medical Wins FDA Clearance for Next-Gen Tablo System - TipRanks
Outset Medical stock jumps after FDA clears next-gen Tablo platform By Investing.com - Investing.com Australia
Outset Medical rises after FDA clears upgraded dialysis system - TradingView
Outset Medical, Inc. Announces FDA Clearance for Next-Gen Tablo Platform - TradingView
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned - The Manila Times
Outset Medical receives FDA clearance for next-generation Tablo dialysis system - StreetInsider
Outset Medical steigt nach FDA-Zulassung für verbessertes Dialysesystem - TradingView
Outset Medical, Inc. to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 11, 2026 - Quiver Quantitative
Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026 - The Manila Times
Dialysis device maker Outset Medical sets Feb. 11 results call - stocktitan.net
Will Outset Medical Inc benefit from geopolitical trends2025 Sector Review & Technical Pattern Based Buy Signals - baoquankhu1.vn
Outset Medical, Inc. (NASDAQ:OM) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Outset Medical Inc Stock (OM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):